Mounjaro Side Effects: Labels, Warnings and What Users Report

Short answer

Mounjaro is a brand of tirzepatide, a dual GLP-1 and GIP receptor agonist approved for type 2 diabetes. The side-effect profile is mainly gastrointestinal — nausea, diarrhoea, vomiting, constipation and abdominal pain — especially early in treatment or when the strength changes. Labels also warn about rarer but serious risks such as pancreatitis, gallbladder disease, dehydration-related kidney problems, low blood sugar when combined with some diabetes drugs, and diabetic eye complications in people with existing retinopathy. Tirzepatide products carry a boxed warning about thyroid C-cell tumours seen in rodents. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.

What the labels list

FDA prescribing information for Mounjaro lists gastrointestinal reactions as the most common. Serious risks on labelling include pancreatitis, gallbladder problems, acute kidney injury often tied to fluid loss, hypoglycaemia with insulin or sulfonylureas, and hypersensitivity reactions. The boxed warning covers thyroid C-cell tumours in rodents; it is not for people with a personal or family history of medullary thyroid carcinoma or MEN 2.

This page summarises public label themes for searchers. It is not a substitute for the full prescribing information. Severe ongoing abdominal pain, signs of dehydration, allergic swelling, vision changes or symptoms of low blood sugar need medical care.

What anonymous users report here

Our tirzepatide side-effects report counts phrase matches across 92 published anonymous confessions tagged tirzepatide (including writers who say Mounjaro, Zepbound or tirz). That is a self-selected sample of stories, not a clinical incidence rate. Live tables, related confessions and methodology: tirzepatide side-effects report and the tirzepatide hub.

How often side effects happen in trials

In the SURPASS diabetes trials, nausea affected roughly 12–18% and diarrhoea roughly 12–17% on Mounjaro, versus lower rates on placebo, mostly while the dose was being increased. Rates were higher in the weight-management trials, where people were dosed for weight loss without diabetes. Last reviewed October 15, 2026.

Diabetes-specific cautions

Low blood sugar is uncommon with Mounjaro alone but more likely with insulin or sulfonylureas, which prescribers may reduce. Rapid improvement in blood sugar can temporarily worsen existing diabetic eye disease, so people with retinopathy are usually monitored. Delayed stomach emptying can affect how other oral drugs are absorbed, including birth control pills.

What users report

#293 credits tirzepatide with bringing HbA1c under 7 for the first time in years. GI complaints are common (#190, #276), and #290 describes a racing heart with low blood pressure that ended in the ER. In Canada: Mounjaro side effects in Canada. Same molecule, weight brand: Zepbound side effects. Versus semaglutide: Mounjaro vs Ozempic and Ozempic side effects.